Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Sees Significant Growth in Short Interest

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totaling 37,392 shares, a growth of 232.8% from the April 15th total of 11,234 shares. Based on an average trading volume of 74,697 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.1% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada lifted its position in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares in the last quarter. Optiver Holding B.V. acquired a new position in Nanobiotix during the third quarter valued at approximately $101,000. Marshall Wace LLP acquired a new position in Nanobiotix during the fourth quarter valued at approximately $220,000. Finally, Millennium Management LLC acquired a new position in Nanobiotix during the fourth quarter valued at approximately $390,000. 38.81% of the stock is owned by institutional investors and hedge funds.

Nanobiotix Price Performance

Shares of NBTX traded up $3.03 during mid-day trading on Thursday, hitting $55.07. The company had a trading volume of 142,428 shares, compared to its average volume of 94,216. The business’s 50-day simple moving average is $34.73 and its 200-day simple moving average is $26.56. Nanobiotix has a 1-year low of $3.60 and a 1-year high of $57.14.

Nanobiotix (NASDAQ:NBTX) last released its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The company had revenue of $3.42 million for the quarter. As a group, sell-side analysts expect that Nanobiotix will post 0.53 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on NBTX. Guggenheim raised their target price on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. TD Cowen restated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. UBS Group raised their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Nanobiotix has an average rating of “Moderate Buy” and a consensus price target of $26.67.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.